SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
+10.1%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$558M
AUM Growth
+$558M
(+14%)
Cap. Flow
+$28M
Cap. Flow
% of AUM
5.02%
Top 10 Holdings %
Top 10 Hldgs %
37.48%
Holding
150
New
25
Increased
36
Reduced
26
Closed
23
Top Buys
| 1 |
CEL
Cellcom Israel, Ltd.
CEL
|
$14.3M |
| 2 |
AGN
Allergan plc
AGN
|
$12.3M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$7.04M |
| 4 |
Merck
MRK
|
$6.72M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$6.38M |
Top Sells
| 1 |
Novartis
NVS
|
$16M |
| 2 |
Bristol-Myers Squibb
BMY
|
$13.8M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$12.2M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$3.99M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$3.63M |
Sector Composition
| 1 | Healthcare | 79.06% |
| 2 | Technology | 7.13% |
| 3 | Communication Services | 3.32% |
| 4 | Industrials | 1.33% |
| 5 | Financials | 1.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $40.1M | 5.72% | 275,000 +25,000 | +10% | +$3.65M |
|
2
Biogen
BIIB
$19.4B
| $32.9M | 4.69% | 105,000 +15,000 | +17% | +$4.7M |
|
|
3
Merck
MRK
$210B
| $27.2M | 3.88% | 425,000 +105,000 | +33% | +$6.72M |
|
4
Gilead Sciences
GILD
$140B
| $18.6M | 2.66% | 230,000 | – | – |
|
5
GSK
GSK
$79.9B
| $18.3M | 2.61% | 450,000 | – | – |
|
6
Sarepta Therapeutics
SRPT
$1.78B
| $17.5M | 2.49% | 384,997 +1,950 | +0.5% | +$88.5K |
|
|
CEL
7
DELISTED
Cellcom Israel, Ltd.
CEL
| $14.3M | 2.04% | +1,535,988 | New | +$14.3M |
|
8
Pfizer
PFE
$141B
| $13.9M | 1.99% | 390,000 | – | – |
|
|
SHPG
9
DELISTED
Shire pic
SHPG
| $13.2M | 1.89% | 86,500 +18,000 | +26% | +$2.76M |
|
|
CLVS
10
DELISTED
Clovis Oncology, Inc.
CLVS
| $13M | 1.86% | 158,000 +65,000 | +70% | +$5.36M |
|
|
AGN
11
DELISTED
Allergan plc
AGN
| $12.3M | 1.75% | +60,000 | New | +$12.3M |
|
|
TSRO
12
DELISTED
TESARO, Inc.
TSRO
| $10.3M | 1.47% | 80,000 +25,000 | +45% | +$3.23M |
|
|
CLLS
13
Cellectis
CLLS
$258M
| $9.92M | 1.42% | 348,736 +144,972 | +71% | +$4.12M |
|
14
Nice
NICE
$8.73B
| $8.88M | 1.27% | 109,159 +24,107 | +28% | +$1.96M |
|
15
Ituran Location and Control
ITRN
$671M
| $8.27M | 1.18% | 229,283 -75,138 | -25% | -$2.71M |
|
16
BioMarin Pharmaceuticals
BMRN
$11.2B
| $7.91M | 1.13% | 85,000 +10,000 | +13% | +$931K |
|
|
PTLA
17
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $7.83M | 1.12% | 145,000 +105,000 | +263% | +$5.67M |
|
18
Aldeyra Therapeutics
ALDX
$351M
| $7.52M | 1.07% | 1,044,131 +168,200 | +19% | +$1.21M |
|
|
ORBK
19
DELISTED
Orbotech Ltd
ORBK
| $7.4M | 1.06% | 175,243 -38,497 | -18% | -$1.62M |
|
|
20
Teva Pharmaceuticals
TEVA
$21.1B
| $7.04M | 1% | +400,000 | New | +$7.04M |
|
21
FibroGen
FGEN
$47.8M
| $6.98M | 1% | 129,779 -35,921 | -22% | -$1.93M |
|
|
RETA
22
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $6.38M | 0.91% | +205,000 | New | +$6.38M |
|
23
Amicus Therapeutics
FOLD
$2.34B
| $6.33M | 0.9% | 420,000 +20,000 | +5% | +$302K |
|
|
IMMU
24
DELISTED
Immunomedics Inc
IMMU
| $6.29M | 0.9% | 450,000 -100,000 | -18% | -$1.4M |
|
|
PVLA
25
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $5.76M | 0.82% | 1,000,000 -100,000 | -9% | -$576K |
|